Liminatus Pharma(LIMN.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Liminatus Pharma
LIMN.US
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
1.951 T
LIMN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Insilico Medicine Signs AI-Driven Drug Collaboration with Qilu Pharma; Insilico Shares Up 5%

    Insilico Medicine Signs AI-Driven Drug Collaboration with Qilu Pharma; Insilico Shares Up 5%

    marketscreener·
    US
    LIMN
    -6.79%
    US
    FBT
    -0.04%
    US
    IBBQ
    +0.34%
    marketscreener·
    US
    LIMN
    -6.79%
    US
    FBT
    -0.04%
    US
    IBBQ
    +0.34%

    Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price

    Aprea Therapeutics Inc. is at risk of being delisted from the Nasdaq due to its common stock trading below the minimum bid price of $1.00 for 30 consecutive business days. The company has 180 days to regain compliance, ending July 22, 2026. Aprea may consider actions like a reverse stock split but cannot guarantee compliance will be achieved.

    Reuters·
    US
    SBIO
    +1.01%
    US
    BIB
    +1.15%
    US
    IBB
    +0.60%
    Reuters·
    US
    SBIO
    +1.01%
    US
    BIB
    +1.15%
    US
    IBB
    +0.60%

    Liminatus Pharma Faces Nasdaq Delisting Over Market Value Rule Breach

    Liminatus Pharma Inc. risks Nasdaq delisting due to non-compliance with listing rules, failing to maintain required market values and asset/revenue criteria. The company is working to address these issues to regain compliance.

    Reuters·
    US
    LIMN
    -6.79%
    Reuters·
    US
    LIMN
    -6.79%

    Pre-market hot trades in US stocks: JX Luxventure pre-market down 8.98%; Liminatus Pharma pre-market up 8.46%

    JX Luxventure pre-market down 8.98%; Liminatus Pharma pre-market up 8.46%; Rubico pre-market up 37.59%; Reliance Global pre-market up 36.04%; Kohl's pre-market up 27.59%

    Tracking Unusual Activity·
    US
    JXG
    -1.18%
    US
    LIMN
    -6.79%
    Tracking Unusual Activity·
    US
    JXG
    -1.18%
    US
    LIMN
    -6.79%

    Liminatus Pharma | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    LIMN
    -6.79%
    LB filings·
    US
    LIMN
    -6.79%
    © 2026 Longbridge｜Disclaimer